deltatrials
Completed INTERVENTIONAL NCT03709043

Addressing Heavy Alcohol Use Consumption With Kudzu (A-HACK)

A-HACK Project: Addressing Heavy Alcohol Use Consumption With Kudzu

Sponsor: Glenn-Milo Santos

Updated 13 times since 2018 Last updated: Apr 27, 2026 Started: Jul 11, 2019 Primary completion: Apr 1, 2024 Completion: Jun 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03709043, this observational or N/A phase trial focuses on Alcohol Use Disorder and Sexually Transmitted Diseases and remains completed. Sponsored by Glenn-Milo Santos, it has been updated 13 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

This study, entitled "The Harness Study" is a double-blind, placebo-controlled, two-arm trial in which 120 binge drinkers with AUD will be randomly assigned to receive 12 weeks of kudzu or placebo, to be taken on an as-needed basis with 1- and 3-month post-treatment follow-up visits. This efficacy study will enroll sexually active, binge drinkers with AUD because they are the most likely population to benefit from this intervention by limiting harms associated with heavy alcohol use and decreasing alcohol-related sexual risk behaviors. A study clinician will perform the Structured Clinical Interview for the DSM-V (SCID) to screen for AUD and determine eligibility. Upon enrollment, 120 participants will be randomized 1:1 to kudzu extract (2 grams) or placebo for targeted administration. Participants will be seen weekly for behavioral surveys, urinalyses, study drug dispensing, and alcohol use counseling. Safety laboratory assessment, vital signs, and the audio computer assisted survey instrument (ACASI) will be completed monthly. Efficacy, tolerability, and acceptability (Specific Aims 1-4) will be assessed upon trial completion as measured by number of binge drinking occasions and numbers of drinks on drinking days via timeline follow-back at weekly visits; number of EtG-positive urine samples; sexual risk behavior data through monthly surveys via...

This study, entitled "The Harness Study" is a double-blind, placebo-controlled, two-arm trial in which 120 binge drinkers with AUD will be randomly assigned to receive 12 weeks of kudzu or placebo, to be taken on an as-needed basis with 1- and 3-month post-treatment follow-up visits. This efficacy study will enroll sexually active, binge drinkers with AUD because they are the most likely population to benefit from this intervention by limiting harms associated with heavy alcohol use and decreasing alcohol-related sexual risk behaviors. A study clinician will perform the Structured Clinical Interview for the DSM-V (SCID) to screen for AUD and determine eligibility. Upon enrollment, 120 participants will be randomized 1:1 to kudzu extract (2 grams) or placebo for targeted administration. Participants will be seen weekly for behavioral surveys, urinalyses, study drug dispensing, and alcohol use counseling. Safety laboratory assessment, vital signs, and the audio computer assisted survey instrument (ACASI) will be completed monthly. Efficacy, tolerability, and acceptability (Specific Aims 1-4) will be assessed upon trial completion as measured by number of binge drinking occasions and numbers of drinks on drinking days via timeline follow-back at weekly visits; number of EtG-positive urine samples; sexual risk behavior data through monthly surveys via ACASI; frequency of adverse events; and cumulative medication adherence data at week 12. Durability of intervention effects will be evaluated at 1- and 3-month post-treatment visits.

Status Flow

~Nov 2018 – ~Dec 2019 · 13 months · monthly snapshot~Dec 2019 – ~Jul 2020 · 7 months · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2022 · 17 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2025 · 13 months · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~May 2026 · 6 months · monthly snapshotMay 4, 2026 – present · 4 months · daily API

Change History

13 versions recorded
  1. May 4, 2026 — Present [daily]

    Completed

    Phase: PHASE2None

  2. Nov 2025 — May 2026 [monthly]

    Completed PHASE2

    Status: UnknownCompleted

  3. Oct 2025 — Nov 2025 [monthly]

    Unknown PHASE2

    Status: Active Not RecruitingUnknown

  4. Sep 2024 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

Show 8 earlier versions
  1. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  2. Sep 2022 — Sep 2023 [monthly]

    Recruiting PHASE2

  3. Apr 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Jul 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  7. Dec 2019 — Jul 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  8. Nov 2018 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

Drinking multiple alcoholic drinks on a single occasion (binge drinking), has many negative health risks but interventions to address this behavior remain limited. This double-blind, placebo-controlled randomized clinical trial will test whether kudzu, an herbal supplement, can reduce heavy alcohol use and alcohol-associated sexual behaviors among sexually-active, binge-drinking individuals at high risk for HIV infection.

Contact Information

Sponsor contact:
  • Glenn-Milo Santos
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations